statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Deutsche Bank AG raised its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report) by 16.4% during the third quarter, according to its most recent disclosure with the...

Deutsche Bank AG Buys 7,282 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report)  Zacks Research decreased their Q1 2024 earnings estimates for shares of Karuna Therapeutics in a research report issued to...

Q1 2024 EPS Estimates for Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reduced by Zacks Research

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Bristol Myers completes acquisition of Karuna Therapeutics

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Get Free Report) has been given an average recommendation of Hold by the sixteen research firms that are currently covering the stock...

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Given Consensus Rating of "Hold" by Analysts

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX  Get Free Report) have received a consensus recommendation of Hold from the sixteen brokerages that are currently covering the...

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Receives Average Recommendation of "Hold" from Brokerages

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report)  Stock analysts at Zacks Research issued their FY2026 earnings estimates for shares of Karuna Therapeutics in a research report...

Karuna Therapeutics, Inc. Expected to Earn FY2026 Earnings of ($4.32) Per Share (NASDAQ:KRTX)

With the business potentially at an important milestone, we thought we'd take a closer look at Karuna Therapeutics...

When Will Karuna Therapeutics, Inc. (NASDAQ:KRTX) Turn A Profit?

This is a Bullish indicator signaling KRTX's price could rise from here. Traders may explore going long the stock or buying call options...

Karuna Therapeutics (KRTX, $329.71) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 14, 2024

This is a signal that KRTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Karuna Therapeutics (KRTX, $329.71) RSI Indicator left the overbought zone on March 14, 2024

Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires...

Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires

Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

Volume	1.87M
52-Wk High	$329.99
52-Wk Low	$158.38

KRTX Karuna Therapeutics Inc

About

Feed

News

Earnings

Fundamentals